FDA Approves Mysterious 'Field Generator Positioning Devices' for Brains
Published Date: 11/26/2025
Rule
Summary
The FDA has officially classified the field generator positioning device as a low-risk, Class I device, making it easier and faster for patients to get access to this helpful technology. This change reduces red tape for manufacturers without compromising safety or effectiveness. The new classification took effect on November 26, 2025, but has been in place since July 10, 2020, so no new costs or delays are expected.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Easier patient access to device
If you are a patient, the FDA has classified the field generator positioning device as Class I (general controls), and says this will enhance patients' access by reducing regulatory burdens. The final order is effective November 26, 2025, and the classification was applicable on July 10, 2020.
Manufacturers face lower premarket burden
If you manufacture or import this device, FDA placed the field generator positioning device in Class I (general controls) and states devices in this type are exempt from premarket notification (510(k)) under section 510(l)(1), except when the device is of substantial importance in preventing impairment of human health or presents a potentially unreasonable risk. FDA says this classification reduces regulatory burdens; the final order is effective November 26, 2025 and was applicable on July 10, 2020.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-21217 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Anchored Esophageal Sheath
The FDA is officially classifying the anchored esophageal sheath as a Class II medical device with special safety rules. This change helps make sure the device is safe and effective while making it easier for patients to get access to this helpful technology. The new rules took effect on November 26, 2025, and could reduce some regulatory hurdles for manufacturers.
Next: 2025-21242 — Extending Deadline for Debtor To Request a Waiver
The VA is giving veterans more time—up to one year instead of 180 days—to ask for a waiver on debts related to benefits. This change, effective January 26, 2026, helps reduce stress by giving veterans extra breathing room to handle their debt issues. It doesn’t cost veterans extra money but makes the process friendlier and fairer.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in